Back to search

Article

Targeted Ablation of Canonical Disulfide Bonds Mitigates TCR Mismatching in Engineered T Cells

2025-06-01

Abstract excerpt

T cell receptor-engineered T (TCR-T) cell therapy holds distinct advantages over chimeric antigen receptor (CAR)-T cell therapy in treating solid tumors by exploiting intracellular targets through MHC-mediated antigen presentation. Despite this potential, only one TCR-T therapy has received FDA approval to date. A key challenge lies in chain mispairing between exogenous therapeutic TCR chains and endogenous TCR ch...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9fbe3f50-f8ec-517c-8f9d-a358b59fd1d4
DOI
10.1101/2025.05.28.656745
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeted Ablation of Canonical Disulfide Bonds Mitigates TCR Mismatching in Engineered T CellsDOI 10.1101/2025.05.28.656745
Select a neighboring publication to make it the new centre.